Centre Francois Baclesse (CFB)

Caen, Normandy 14076

2 studies enrolling now · 4 studies all time

What they study most

Endometrial Cancer, Fallopian Tube Cancer, Low-grade Serous Ovarian Cancer, Melanoma, NSCLC, Ovarian Cancer, Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Cancer, Recurrent Primary Peritoneal Cancer

Studies at this site

• Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers — Recruiting now
• A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer — Recruiting now
• A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab — Recruiting now
• A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery — Running, not enrolling